Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 111 articles:
HTML format



Single Articles


    May 2021
  1. XU X, Wang Y, Bryce NS, Tang K, et al
    Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
    PubMed     Abstract available


    March 2021
  2. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
    Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
    PubMed     Abstract available


  3. ZHANG X, Ling MT, Feng H, Wong YC, et al
    Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
    PubMed    


    February 2021
  4. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    January 2021
  5. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    PubMed     Abstract available


  6. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    PubMed     Abstract available


  7. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    PubMed     Abstract available


    December 2020
  8. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  9. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    PubMed     Abstract available


    September 2020
  10. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    PubMed     Abstract available


    August 2020
  11. PHELPS DL, Saso S, Ghaem-Maghami S
    Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01035.
    PubMed     Abstract available


  12. YANG M, Zhang G, Wang Y, He M, et al
    Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
    Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
    PubMed     Abstract available


    July 2020
  13. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    PubMed     Abstract available


    June 2020
  14. MARTINS FC, Couturier DL, Paterson A, Karnezis AN, et al
    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Br J Cancer. 2020 Jun 18. pii: 10.1038/s41416-020-0900.
    PubMed     Abstract available


  15. VAN WEELDEN WJ, van der Putten LJM, Inda MA, van Brussel A, et al
    Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0925.
    PubMed     Abstract available


    May 2020
  16. JIANG YX, Siu MK, Wang JJ, Mo XT, et al
    Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0865.
    PubMed     Abstract available


  17. BOCHNER F, Fellus-Alyagor L, Ketter D, Golani O, et al
    Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0878.
    PubMed     Abstract available


  18. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    PubMed     Abstract available


    April 2020
  19. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0849.
    PubMed     Abstract available


  20. MONTFORT A, Owen S, Piskorz AM, Supernat A, et al
    Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Br J Cancer. 2020 Apr 6. pii: 10.1038/s41416-020-0822.
    PubMed     Abstract available


  21. ZHAO Y, He M, Cui L, Gao M, et al
    Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0825.
    PubMed     Abstract available


    February 2020
  22. MASOODI T, Siraj S, Siraj AK, Azam S, et al
    Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Br J Cancer. 2020 Feb 26. pii: 10.1038/s41416-020-0763.
    PubMed     Abstract available


  23. BERG HF, Ju Z, Myrvold M, Fasmer KE, et al
    Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0745.
    PubMed     Abstract available


  24. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed     Abstract available


    January 2020
  25. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    PubMed     Abstract available


  26. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    PubMed     Abstract available


  27. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    PubMed     Abstract available


  28. LIU N, Lin X, Huang C
    Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
    Br J Cancer. 2020;122:279-292.
    PubMed     Abstract available


    December 2019
  29. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    PubMed     Abstract available


  30. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    PubMed     Abstract available


    November 2019
  31. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    PubMed     Abstract available


  32. ANNETT S, Moore G, Short A, Marshall A, et al
    FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Br J Cancer. 2019 Nov 27. pii: 10.1038/s41416-019-0649.
    PubMed     Abstract available


    October 2019
  33. HAMESTER F, Legler K, Wichert B, Kelle N, et al
    Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
    Br J Cancer. 2019 Oct 29. pii: 10.1038/s41416-019-0607.
    PubMed     Abstract available


    September 2019
  34. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


  35. COLOMBO N, Zaccarelli E, Baldoni A, Frezzini S, et al
    Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2019 Sep 20. pii: 10.1038/s41416-019-0584.
    PubMed     Abstract available


    August 2019
  36. TASSI RA, Gambino A, Ardighieri L, Bignotti E, et al
    FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Br J Cancer. 2019 Aug 22. pii: 10.1038/s41416-019-0553.
    PubMed     Abstract available


  37. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0544.
    PubMed     Abstract available


  38. SHI T, Jiang R, Pu H, Yang H, et al
    Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Br J Cancer. 2019 Aug 6. pii: 10.1038/s41416-019-0543.
    PubMed     Abstract available


    July 2019
  39. LEVASSEUR N, Chia S
    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
    Br J Cancer. 2019;121:1-2.
    PubMed     Abstract available


  40. BERNDSEN RH, Castrogiovanni C, Weiss A, Rausch M, et al
    Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Br J Cancer. 2019;121:139-149.
    PubMed     Abstract available


    June 2019
  41. QIAN F, Rookus MA, Leslie G, Risch HA, et al
    Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2019 Jun 19. pii: 10.1038/s41416-019-0492.
    PubMed     Abstract available


  42. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    PubMed     Abstract available


    March 2019
  43. FORTNER RT, Terry KL, Bender N, Brenner N, et al
    Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0422.
    PubMed     Abstract available


  44. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Mar 19. pii: 10.1038/s41416-019-0425.
    PubMed     Abstract available


    February 2019
  45. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Abstract available


    January 2019
  46. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Abstract available


  47. MULATI K, Hamanishi J, Matsumura N, Chamoto K, et al
    VISTA expressed in tumour cells regulates T cell function.
    Br J Cancer. 2019;120:115-127.
    PubMed     Abstract available


    December 2018
  48. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Abstract available


    October 2018
  49. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Abstract available


  50. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Abstract available


  51. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Abstract available


  52. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    PubMed     Abstract available


  53. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Abstract available


  54. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    PubMed     Abstract available


    August 2018
  55. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Abstract available


    July 2018
  56. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Abstract available


  57. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Abstract available


  58. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    PubMed    


  59. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    PubMed    


    June 2018
  60. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Abstract available


  61. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    PubMed     Abstract available


  62. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
    Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
    PubMed     Abstract available


  63. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Abstract available


  64. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    PubMed     Abstract available


    March 2018
  65. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    PubMed     Abstract available


  66. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Abstract available


    February 2018
  67. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Abstract available


    January 2018
  68. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    December 2017
  69. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
    Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    November 2017
  70. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  71. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    September 2017
  72. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Abstract available


  73. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    August 2017
  74. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Abstract available


  75. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Abstract available


  76. MINLIKEEVA AN, Freudenheim JL, Cannioto RA, Eng KH, et al
    History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  77. CHEN Y, Wang DD, Wu YP, Su D, et al
    MDM2 promotes epithelial-mesenchymal transition and metastasis of ovarian cancer SKOV3 cells.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  78. SHARMA R, Huang X, Brekken RA, Schroit AJ, et al
    Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies.
    Br J Cancer. 2017;117:545-552.
    PubMed     Abstract available


  79. TABUNG FK, Huang T, Giovannucci EL, Smith-Warner SA, et al
    The inflammatory potential of diet and ovarian cancer risk: results from two prospective cohort studies.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  80. MENON U, McGuire AJ, Raikou M, Ryan A, et al
    The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  81. ITAMOCHI H, Oishi T, Oumi N, Takeuchi S, et al
    Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    June 2017
  82. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  83. SERENI MI, Baldelli E, Gambara G, Ravaggi A, et al
    Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  84. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Abstract available


  85. BANDERA EV, Lee VS, Qin B, Rodriguez-Rodriguez L, et al
    Impact of body mass index on ovarian cancer survival varies by stage.
    Br J Cancer. 2017 Jun 6. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  86. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Abstract available


    May 2017
  87. PLAYDON MC, Nagle CM, Ibiebele TI, Ferrucci LM, et al
    Pre-diagnosis diet and survival after a diagnosis of ovarian cancer.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    April 2017
  88. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  89. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2017 Mar 30. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  90. DIXON SC, Nagle CM, Wentzensen N, Trabert B, et al
    Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  91. PHELPS DL, Borley JV, Flower KJ, Dina R, et al
    Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.
    Br J Cancer. 2017 Mar 28. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  92. BEGG CB, Rice MS, Zabor EC, Tworoger SS, et al
    Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  93. FALLOWFIELD L, Solis-Trapala I, Menon U, Langridge C, et al
    The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  94. SHATHASIVAM P, Kollara A, Spybey T, Park S, et al
    VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    February 2017
  95. KIM SJ, Rosen B, Fan I, Ivanova A, et al
    Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    January 2017
  96. LINDEMANN K, Gibbs E, Avall-Lundqvist E, dePont Christensen R, et al
    Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).
    Br J Cancer. 2017 Jan 24. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  97. KAR SP, Adler E, Tyrer J, Hazelett D, et al
    Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  98. HEUDEL PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, et al
    Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    December 2016
  99. KOMMOSS S, Kommoss F, Diebold J, Lax S, et al
    Better resource utilisation and quality of care for ovarian cancer patients using internet-based pathology review.
    Br J Cancer. 2016 Dec 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  100. COOK LS, Pestak CR, Leung AC, Steed H, et al
    Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  101. LICAJ I, Jacobsen BK, Selmer RM, Maskarinec G, et al
    Smoking and risk of ovarian cancer by histological subtypes: an analysis among 300 000 Norwegian women.
    Br J Cancer. 2016 Dec 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    November 2016
  102. LI X, Chen W, Zeng W, Wan C, et al
    microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP.
    Br J Cancer. 2016 Nov 22. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  103. LEDERMANN JA, Harter P, Gourley C, Friedlander M, et al
    Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    Br J Cancer. 2016 Nov 8. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    October 2016
  104. ZAAIJER LH, van Doorn HC, Mourits MJ, van Beurden M, et al
    Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2016 Oct 18. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  105. KONECNY GE, Kristeleit RS
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  106. SHAFRIR AL, Babic A, Tamimi RM, Rosner BA, et al
    Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    September 2016
  107. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  108. DONAT-VARGAS C, Akesson A, Berglund M, Glynn A, et al
    Dietary exposure to polychlorinated biphenyls and risk of breast, endometrial and ovarian cancer in a prospective cohort.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  109. QIN B, Moorman PG, Alberg AJ, Barnholtz-Sloan JS, et al
    Dairy, calcium, vitamin D and ovarian cancer risk in African-American women.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  110. KOMMOSS S, Gilks CB, du Bois A, Kommoss F, et al
    Ovarian carcinoma diagnosis: the clinical impact of 15 years of change.
    Br J Cancer. 2016 Sep 15. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


    August 2016
  111. VAN DER PUTTEN LJ, Visser NC, van de Vijver K, Santacana M, et al
    L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
    Br J Cancer. 2016 Aug 9. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: